Human anti-PD-1 or anti-PD-L1 antibodies result in durable tumor response and significantly improve survival in advanced melanoma [27], renal cell carcinoma [28] and NSCLC [29]. This evidence concerns the gene CD274 and hereditary clear cell renal cell carcinoma.